Related Experiment Video
Updated: May 12, 2026
A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy
Published on: November 3, 2016
Integrated Approaches and Practical Recommendations in Patient Care Identified with 5q Spinal Muscular Atrophy
Vanessa L Romanelli Tavares1, Rodrigo Holanda Mendonça2, Maytê S Toledo1
1Newborn Screening Reference Center, Instituto Jô Clemente (IJC), São Paulo 04040-033, Brazil.
Insights
Early diagnosis of 5q Spinal Muscular Atrophy (SMA) is vital for better outcomes. This study explores implementing newborn screening for 5q-SMA in Brazil, addressing unique challenges and opportunities.
Area of Science:
- Neurology
- Genetics
- Public Health
Background:
- 5q Spinal Muscular Atrophy (SMA) is a severe genetic neuromuscular disorder characterized by motor neuron degeneration.
- Early diagnosis and intervention significantly improve clinical outcomes and patient prognosis.
- Current therapeutic advancements highlight the critical need for widespread newborn screening programs.
Purpose of the Study:
- To address key considerations for integrating 5q-SMA screening into Brazil's National Newborn Screening Program.
- To explore Brazil's specific challenges and opportunities in implementing a national SMA screening initiative.
- To guide healthcare professionals and policymakers in establishing effective SMA care pathways.
Main Methods:
- Review of current 5q-SMA diagnostic and therapeutic strategies.
- Analysis of logistical and clinical factors for newborn screening implementation in Brazil.
- Examination of genetic testing, patient referral timelines, and treatment algorithm considerations.
Main Results:
- Early detection through newborn screening is crucial for timely intervention in 5q-SMA.
- Brazil faces unique challenges in program implementation, including genetic testing access and referral networks.
- Standardized protocols for screening, referral, and treatment are essential for program success.
Conclusions:
- Implementing a national 5q-SMA newborn screening program in Brazil is feasible and necessary.
- Addressing logistical and healthcare system challenges is critical for effective program execution.
- This initiative aims to improve care for Brazilian newborns diagnosed with 5q-SMA and foster regional collaboration.
Abstract:
In recent years, significant progress has been made in 5q Spinal Muscular Atrophy therapeutics, emphasizing the importance of early diagnosis and intervention for better clinical outcomes. Characterized by spinal cord motor neuron degeneration, 5q-SMA leads to muscle weakness, swallowing difficulties, respiratory insufficiency, and skeletal deformities. Recognizing the pre-symptomatic phases supported by screening and confirmatory genetic tests is crucial for early diagnosis. This work addresses key considerations in implementing 5q-SMA screening within the Brazilian National Newborn Screening Program and explores Brazil's unique challenges and opportunities, including genetic tests, time-to-patient referral to specialized centers, program follow-up, and treatment algorithms. We aim to guide healthcare professionals and policymakers, facilitating global discussions, including Latin American countries, and knowledge-sharing on this critical subject to improve the care for newborns identified with 5q SMA.
